Ipca Laboratories Ltd. (IPCALAB) fundamentals
Ipca Laboratories Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as IPCALAB (ISIN INE571A01038). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Ipca Laboratories Ltd. does
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is engaged in manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The Company’s products are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc. and Ipca Pharma Nigeria Ltd.
Valuation and market data
| Last close | ₹1964.20 |
|---|---|
| Market capitalisation | ₹52,025 crore |
| Enterprise value | ₹51,498 crore |
| P/E (TTM) | 43.67 |
| Price to book | 5.46 |
| Price to sales (TTM) | 2.98 |
| Book value per share | ₹359.58 |
| Dividend yield | 30.55% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Wed Feb 08 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹7,431 crore | ₹1,532 crore | ₹1,133 crore | 44.64 |
| Mar 2025 | ₹6,749 crore | ₹1,000 crore | ₹651 crore | 25.65 |
| Mar 2024 | ₹6,278 crore | ₹822 crore | ₹530 crore | 20.91 |
| Mar 2023 | ₹5,926 crore | ₹750 crore | ₹506 crore | 19.93 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 44.7% |
|---|---|
| Foreign institutions (FII) | 10.7% |
| Mutual funds | 31.1% |
| Other domestic institutions | 6.2% |
| Retail and others | 7.2% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.